Search

Illumina Inc

Atvērts

SektorsVeselības aprūpe

218.66 2.82

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

209.29

Max

220

Galvenie mērījumi

By Trading Economics

Ienākumi

-268M

-134M

Pārdošana

68M

1.2B

P/E

Sektora vidējais

35.568

57.371

EPS

1.31

Peļņas marža

-11.562

Darbinieki

8,600

EBITDA

80M

330M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-8.59% downside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 29. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

497M

29B

Iepriekšējā atvēršanas cena

215.84

Iepriekšējā slēgšanas cena

218.66

Ziņu noskaņojums

By Acuity

23%

77%

78 / 340 Rangs Healthcare

Illumina Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. aug. 20:02 UTC

Illumina Inc's shares are higher today, building on gains since Wednesday. The stock is trading near the upper end of its one-month range.

2026. g. 19. aug. 20:02 UTC

Correlated Moves

Illumina Inc. shares are higher, buoyed by strong momentum in the genomics sector and a notable rise in the ARK Genomic Revolution ETF.

2026. g. 17. aug. 19:54 UTC

News

Illumina Inc's stock is higher, supported by a Yahoo Finance article discussing its price target of $198.89 and concerns over organic sales performance.

2026. g. 13. aug. 20:06 UTC

Illumina Inc's shares are lower amid declines in the Life Sciences Tools & Services sector, with no specific company news identified for the movement.

2026. g. 12. aug. 22:02 UTC

Illumina Inc shares are lower in after-market hours with no specific news identified. Broader market conditions reflect mixed performance amid inflation data.

2026. g. 11. aug. 19:16 UTC

Illumina Inc. shares are trading higher, recovering from an early dip during Tuesday's session. No specific news or developments were identified.

2026. g. 10. aug. 23:16 UTC

Correlated Moves

Illumina Inc shares fell in after-hours trading, tracking a broader decline in the Russell 2000 Index amid rising U.S. Treasury yields and inflation concerns.

2026. g. 7. aug. 19:46 UTC

News

Illumina Inc shares are lower after Director Keith A. Meister sold 283,269 shares, raising investor concerns about the company's valuation.

2026. g. 6. aug. 23:06 UTC

Illumina Inc shares are lower in after-market trading following Thursday's close, despite an initial uptick. No specific news was identified to explain the decline.

2026. g. 5. aug. 19:52 UTC

Correlated Moves

Illumina shares are lower following disappointing first-quarter results and broader market declines. ADP's report on weak job growth has added to cautious sentiment.

2026. g. 4. aug. 19:31 UTC

Correlated Moves

Illumina Inc's shares are higher today, reflecting a broader market trend as the Russell 2000 Index also advances. The stock is near its one-month range high.

2026. g. 3. aug. 20:03 UTC

News

Illumina shares are lower today as Citigroup maintains a Sell rating and raises its price target to $113 amid mixed analyst sentiment.

2026. g. 31. jūl. 23:06 UTC

News

Illumina Inc reported strong Q2 results and raised full-year guidance, yet shares declined in after-market trading from Friday's close of $202.95.

2026. g. 30. jūl. 23:41 UTC

News
Social Media

Illumina Inc shares declined in after-market trading despite strong second-quarter results and raised full-year EPS guidance, reflecting concerns over falling net income.

2026. g. 29. jūl. 23:26 UTC

Illumina Inc. shares declined after-market amid overall market volatility following the Federal Reserve's decision to maintain interest rates amid rising inflation concerns.

2026. g. 28. jūl. 19:46 UTC

News

Illumina Inc. is acquiring contingent payments from its merger with Treeline Biosciences to enhance integration. Shares are trading higher since Monday's close.

2026. g. 27. jūl. 23:26 UTC

Illumina Inc shares are lower in after-market hours, continuing a decline over the past three sessions with no specific news identified.

2026. g. 24. jūl. 17:46 UTC

Illumina Inc's shares are lower today, hitting a mid-morning low. Broader market sentiment may be affected by recent volatility in oil prices.

2026. g. 22. jūl. 19:31 UTC

News

Illumina Inc shares are lower amid a report citing stagnant sales and concerns over management's investment opportunities. The company may need acquisitions for growth.

2026. g. 21. jūl. 20:02 UTC

Correlated Moves
News

Illumina Inc's shares are higher, supported by broader market momentum and anticipation of upcoming earnings from major companies. The Russell 2000 Index also advanced.

2026. g. 20. jūl. 19:56 UTC

Correlated Moves

Illumina Inc shares declined during Monday's session, paralleling a drop in the ARK Genomic Revolution ETF amid broader market weakness.

2026. g. 17. jūl. 19:06 UTC

Illumina Inc shares are lower today amid broader market declines, particularly in technology and semiconductor stocks, following significant selling pressure in Asia.

2026. g. 16. jūl. 22:06 UTC

Illumina Inc shares are lower in after-market hours, tracking broader market declines amid geopolitical tensions and mixed economic indicators.

2026. g. 15. jūl. 18:51 UTC

Illumina Inc shares declined Wednesday, pulling back from earlier gains. No specific news was identified to explain this movement amid broader positive market trends.

2026. g. 14. jūl. 19:36 UTC

News

Illumina shares rise as Canaccord raises price target to $190.00, despite a patent ruling against the company in Germany.

2026. g. 10. jūl. 20:06 UTC

Correlated Moves

Illumina Inc shares are lower amid a broader decline in the biotechnology sector. Market volatility is heightened due to geopolitical tensions involving the U.S. and Iran.

2026. g. 9. jūl. 19:11 UTC

News
Correlated Moves

Illumina Inc. appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, contributing to a rise in shares amid sector gains.

2026. g. 8. jūl. 20:04 UTC

Correlated Moves

Illumina Inc shares are lower today, influenced by declines in the Life Sciences Tools & Services sector and a drop in the Russell 2000 Index.

2026. g. 7. jūl. 21:41 UTC

Illumina Inc. shares are higher in after-market trading, reflecting ongoing strength despite earlier session pullbacks and broader caution in the technology sector.

2026. g. 6. jūl. 19:52 UTC

Social Media
News

Evercore ISI raised its price target on Illumina to $200, maintaining an Outperform rating. Shares are trading higher amid positive sentiment and social media discussions.

Salīdzinājums

Cenas izmaiņa

Illumina Inc Prognoze

Cenas mērķis

By TipRanks

-8.59% uz leju

Prognoze 12 mēnešiem

Vidējais 194.93 USD  -8.59%

Augstākais 230 USD

Zemākais 113 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Illumina Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

15 ratings

7

Pirkt

5

Turēt

3

Pārdot

Noskaņojums

By Acuity

78 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
help-icon Live chat